All the Drug Class Drugs
Immunoglobulins. Human Normal Immunoglobulin 160 mg/ml. PFS: 1 x 2 cc, 5 cc. See lit.
Defic. defect. antibody synth., protracted
transitory hypogammaglobulem.,
proph. hepatit. A, measles or attenuat.
measles.
C/I: Severe thrombocytopen., other
coag. disords., isolated immunoglobulin
A (IgA) defic.
Immunoglobulins. Trastuzumab deruxtecan 20 mg/ml. Vial. Pwder for sol. for inf.
5.4 mg/kg given as IV infus. once every 3 weeks (21-day cycle) until dis. progression or unacceptable tox. For gastric cancer dose is 6.4 mg/kg .Do not substitute this drug for or with trastuzumab or ado-trastuzumab emtansine.
HER2-Pos. Metast. Breast Cancer: tmt. of adults with unresectable or metast. HER2-pos. (IHC 3+ or ISH pos.) breast cancer who have received a prior anti-HER2-based regim. either:• in the metast. setting, or• in the neoadj. or adj. setting and have developed dis. recurrence during or within six months of completing ther. HER2-Low and HER2-Ultralow Metast. Breast Cancer: tmt. of adults with unresectable or metast.•Hormone receptor (HR)-pos. HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, that has progressed on one or more endocr. ther. in the metast. setting.•HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemother. in the metast. setting or developed dis. recurrence during or within 6 months of completing adj. chemother.HER2-Mutant Unresectable or Metast. Non-Small Cell Lung Cancer:tmt. of adults with unresectable or metast. non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutat., as detected by an approved test, and who have received a prior syst. ther.HER2-Pos. Locally Adv. or Metast. Gastric Cancer: tmt. of adults with locally adv. or metast. HER2-pos. (IHC 3+ or IHC 2+/ISH pos.) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regim. HER2-Positive (IHC 3+) Unresectable or Metast. Solid Tumor: tmt. of adults with unresectable or metast. HER2-pos. (IHC 3+) solid tumors who have received prior syst. tmt. and have no satisfact. alternat. options.
C/I: Hypersens.
Immunoglobulins. Human Immunoglobulin 50mg/ml. VIAL: 20 ml, 50 ml, 100 ml, 200 ml. The dose & dose regimen is depend. on the indicat. for each pt. depend. on the clin. response. Pts. bdywt. may require adjust. in underweight /overweight pts. See lit.
Replac. ther. in adult., child.,adolesc. (0-18 years) in:
Prim. immunodefic. syndr. (PID) with impair. antibod. product.
Second. immunodeficiencies (SID) in pts. who suffer from severe or recur.infect., ineffect. antimicrob. tmt. and either proven specific antibod. fail. (PSAF)* or serum IgG level of <4 g/l.
* PSAF = fail. to mount at least a 2-fold rise in IgG antibody titre to pneumococcal
polysaccharide and polypeptide antigen vaccin.
Immunomodulation in adult., and child. and adolesc. (0-18 years) in:
ITP, in pts. at high risk of bleed. or prior to surgery to correct the platelet count.
Guillain Barré syndr.
Kawasaki dis. (in conjunct. with acetylsalicyl. a.; See Lit.
Chronic inflammat. demyelinate. poliradiculoneuropathy (CIDP).
Multifoc.motor neuropath. (MMN).
C/I: Hypersens.
Pts. with selective IgA defic. who develop. antibodies to IgA, as administering an IgA contain. product can result in anaphylaxis.
Human Monoclonal Antibody, Immunoglobulins. Durvalumab 50 mg/ml. Vial: Sol for inf.120/500 mg
Dosage and freq. depend on patient weight, disease type and monoor combined ther. See lit.
Urothelial Carcinoma: for pts with PD-L1 high (Tumor cell ≥25% or IC ≥25%) locally adv. or metast. urothelial carcinoma who:
- have dis. progr. during or following platinum-contain. chemother
. - have dis. progr. within 12 months of neoadj. or adj. tmt with platinum cont. chemother..
Non-Small Cell Lung Cancer - for pts with unresect. Stage III non-small cell lung cancer (NSCLC) whose dis. has not progr. following concurr.platinum-based chemother. and radiation ther.- in comb. with tremelimumab and platinum-based chemother. for the first-line tmt. of adlts with metast. NSCLC with no sensit. EGFR mutat. or ALK pos. mut..
Small Cell Lung Cancer, in combin. with etoposide and either carboplatin or cisplatin, for the first-line tmt. of adlt pts. with extens.-stage small cell lung cancer (ES-SCLC).
Biliary Tract Cancers: in comb. with gemcitabine and cisplatin for the first-line tmt of adlts with locally adv., unresect., or metast. biliary tract cancer (BTC).
Hepatocellular Carcinoma: in comb. with tremelimumab for the first line tmt of adlts with adv. or unresect. hepatocellular carcinoma (HCC).
C/I: Hypersens.
Immunoglobulins. Human Normal Immunoglobulin 100 g/l. VIAL (sol.for infus.): 10, 25, 50, 100, 200 ml.
Replacem. ther. in primary immunodefic., init. dose: 0.4-0.8 g/kg, thereafter 0.2-0.8 g/kg every 3-4 wks. to obtain IgG trough level of IgG of at least 6 g/l. Replacem. ther. in second. immunodefic.: 0.2-0.4 g/kg, every 3-4 wks. Prim. immune thrombocytop.: 0.8-1 g/kg on day 1, possibly rpt once within 3 days, or 0.4 g/kg/d for 2-5 d. Guillain Barré syndr.: 0.4 g/kg/d for 5 d (possible rpt of dosing in case of relapse). Kawasaki dis.: 2 g/kg should be admin. as a sgle. dose. Pts should receive concom. tmt with acetylsalicylic acid. CIDP Starting dose: 2 g/kg div. over 2 -5 consecutive d. Mainten. doses: 1 g/kg over 1-2 consecutive d every 3 wks. MMN starting dose: 2 g/kg given over 2-5 consecut. days. Mainten. dose: 1 g/kg every 2 to 4 wks or 2 g/kg every 4 to 8 wks. Replacem. ther. in adults, child. and adolesc. (0-18 years) in: Primary immunodefic. syndr. (PID) with impair. antibod. prod. Second. Immunodefic. (SID) in pts with sev. or recur. infect., ineffective antimicrob. tmt and either PSAF or serum IgG level of <4 g/l. Immunomodul. in adults, child. and adolesc. (0-18 years) in:Primary ITP, in pts at high risk of bleed. or prior to surg. to correct platelet count. Guillain Barré syndr. Kawasaki dis. (in conjunct. w/acetylsalicylic acid). Chronic inflamm. demyelin. polyradiculoneuropathy (CIDP). Multifocal motor neuropathy (MMN).
C/I: Hypersens. to the active subst. or to any of the excip. Pts. with selective IgA defic. who develop antibod. to IgA, as admin. of IgA-contain. product can result in anaphylax.
Immunoglobulins. Human Normal Immunoglobulin 50 mg/ml. VIAL (sol.for infus.): 20, 50, 100, 200 ml.
Replacem. ther. in primary immunodefic., init. dose: 0.4-0.8 g/kg, thereafter 0.2-0.8 g/kg every 3-4 wks. to obtain IgG trough level of IgG of at least 6 g/l. Replacem. ther. in second. immunodefic.: 0.2-0.4 g/kg, every 3-4 wks. Prim. immune thrombocytop.: 0.8-1 g/kg on day 1, possibly rpt once within 3 days, or 0.4 g/kg/d for 2-5 d. Guillain Barré syndr.: 0.4 g/kg/d for 5 d (possible rpt of dosing in case of relapse). Kawasaki dis.: 2 g/kg should be admin. as a sgle. dose. Pts should receive concom. tmt with acetylsalicylic acid. CIDP Starting dose: 2 g/kg div. over 2 -5 consecutive d. Mainten. doses: 1 g/kg over 1-2 consecutive d every 3 wks. MMN starting dose: 2 g/kg given over 2-5 consecut. days. Mainten. dose: 1 g/kg every 2 to 4 wks or 2 g/kg every 4 to 8 wks. Replacem. ther. in adults, child. and adolesc. (0-18 years) in: Primary immunodefic. syndr. (PID) with impair. antibod. prod. Second. Immunodefic. (SID) in pts with sev. or recur. infect., ineffective antimicrob. tmt and either PSAF or serum IgG level of <4 g/l. Immunomodul. in adults, child. and adolesc. (0-18 years) in:Primary ITP, in pts at high risk of bleed. or prior to surg. to correct platelet count. Guillain Barré syndr. Kawasaki dis. (in conjunct. w/acetylsalicylic acid). Chronic inflamm. demyelin. polyradiculoneuropathy (CIDP). Multifocal motor neuropathy (MMN).
C/I: Hypersens. to the active subst. or to any of the excip. Pts. with selective IgA defic. who develop antibod. to IgA, as admin. of IgA-contain. product can result in anaphylax.
